Clinical trials: Treatment Resistant Major Depressive Disorder
Depression - Major Depressive Disorder, Treatment Resistant Depression
ipRGC as a Potential Biomarker for Predicting Transcranial Magnetic Stimulation Treatment Response in Major Depressive Disorder
This research explores the potential of retinal ganglion cells (RGCs), particularly intrinsically photosensitive RGCs (ipRGCs), as biomarkers for predicting response to transcranial magnetic stimulation (TMS) in…
- Trial name
- BRIGHT (NCT07474974)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- Portugal
- Volunteers
- 44 people
- Sponsor
- Polytechnic Institute of Porto
Unipolar Depression, Treatment Resistant Depression
Home-administered tDCS for Treatment of Depression
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT.
- Trial name
- NCT04781127
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Soterix Medical
Treatment-resistant Depression, Major Depressive Disorder
Physical Activity Program for TRD
This is a pilot study examining the delivery of a remotely delivered, one-on-one, individualized physical activity (PA) program in adult participants with treatment-resistant depression (TRD).
- Trial name
- NCT06404320
- Testing
- PA program - MoveU.HappyU
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
Major Depressive Disorder, Depression
Buprenorphine Used With Treatment Resistant Depression in Older Adults
The investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patients with difficult to treat depression.
- Trial name
- IRLGreyB (NCT02181231)
- Testing
- venlafaxine XR, buprenorphine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Treatment Resistant Depression
TBS in Major Depression
Background Major depression is associated with morbidity and increased mortality. Along with the psychological strain depression represents a high socioeconomic burden costing Europe more than €113 billion/year.
- Trial name
- NCT03257397
- Testing
- theta-burst stimulation (TBS) using a MagPro X1000
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Rupert Lanzenberger
Major Depressive Disorder
Randomized Controlled Trial of Conventional vs Theta Burst rTMS
This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the standard conventional high frequency left sided stimulation protocol.
- Trial name
- HFL vs TBS (NCT01887782)
- Testing
- HFL rTMS, iTBS
- Where
- 3 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Centre for Addiction and Mental Health
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Behavioural Activation Therapy and Esketamine for Resistant Depression
This is a randomized clinical trial to test the effectiveness of combining a proven psychological intervention called behavioural activation therapy alongside esketamine treatment for treatment resistant major depressive episodes…
- Conditions
- Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major, Bipolar Disorder
- Trial name
- NCT06431386
- Testing
- Behavioural Activation (BA) Therapy, Esketamine
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- The Royal's Institute of Mental Health Research
Depressive Disorder, Major
Peripheral Immunomarker Validation in Treatment-resistant Depression
This is a study to characterise the role of inflammatory processes in depression. There is compelling evidence that inflammation is often associated with, and can cause, depression.
- Trial name
- BIODEP (NCT02752178)
- Testing
- MA, DEP
- Where
- 5 sites in United Kingdom
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- University of Cambridge
Major Depressive Disorder, Treatment Resistant Depression
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical…
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Trial name
- NCT03573349
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Magnetic Resonance Imaging, Major Depression
Ketamine Alcohol (in Treatment-Resistant Depression)
A single subanesthetic dose infusion of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has rapid and robust antidepressant effects in patients with treatment-refractory major depressive disorder (TRD).
- Conditions
- Magnetic Resonance Imaging, Major Depression, Alcoholism
- Trial name
- NCT02122562
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mark Niciu
Major Depression
Use of Risperidone in ECT for Treatment Resistant Depression
The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
- Trial name
- NCT00203723
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression - Major Depressive Disorder, Depression Bipolar
Mental Health Mission Mood Disorder Cohort Study
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures…
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Trial name
- NCT07189689
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Oxford
Depression
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication…
- Trial name
- NCT00021528
- Testing
- citalopram, BuproprionSR, buspirone
- Where
- 41 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Low Field Magnetic Stimulation for Treatment Resistant Depression
This is a double-blind, randomized, sham-controlled phase II study of the effects of Low Field Magnetic Stimulation (LFMS) on brain circuitry of adults with treatment-resistant Major Depressive Disorder (MDD).
- Trial name
- NCT01944644
- Testing
- Active Low Field Magnetic Stimulation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
Ketamine for Treatment Resistant MDD
This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IM/SC ketamine for treatment resistant MDD.
- Trial name
- NCT04021433
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depressive Disorder (MDD)
Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have…
- Trial name
- NACC-D (NCT07212465)
- Testing
- Active Brainsway H7-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Rotman Research Institute at Baycrest
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne